Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CY 1747

Drug Profile

CY 1747

Alternative Names: CY-1747; PB1.3

Latest Information Update: 23 Apr 1999

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Epimmune
  • Developer Epimmune; Sumitomo Pharmaceuticals
  • Class Anti-ischaemics; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cerebrovascular disorders; Ischaemic heart disorders

Most Recent Events

  • 12 Jan 1996 An animal study has been added to the Thromboses pharmacodynamics section
  • 28 Aug 1995 Discontinued-Preclinical for Cerebrovascular disorders in USA (Unknown route)
  • 28 Aug 1995 Discontinued-Preclinical for Ischaemic heart disorders in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top